Skip to main content
. 2019 Mar 29;10:309. doi: 10.3389/fphar.2019.00309

FIGURE 4.

FIGURE 4

Chemogenetic inhibition of novelty-induced hyperlocomotion in Gria1-/- mice. (A) Virus injection resulted in hM4Gi-mCherry expression in the dorsal hippocampus. Hb, habenula; fi, fimbria; scale bar: 1 mm. (B) A close-up photograph displaying transduced neurons and neurites in the dentate gyrus. No transduced neurites were observed outside the hippocampus (not shown). Gr, granule cell layer; Mol, molecular layer; scale bar: 50 μm. (C) Distance traveled in a novel environment in 5-min periods in mice transduced with DREADDs. (D) Total distance traveled during the 30-min trial in mice transduced with DREADDs. ∗∗P < 0.01 and ∗∗∗P < 0.001 for the significances of the differences between the genotypes after vehicle; #P < 0.05 and ##P < 0.01 between vehicle and CNO treatments within the same genotype (Bonferroni post-test), n = 10 for both genotypes. (E) Distance traveled in a novel environment in 5-min periods in non-DREADD expressing WT and Gria1-/- control mice. ∗∗∗P < 0.001 for the significances within drug treatment and between genotypes (ANOVA). (F) Total distance traveled during the 30-min trial in non-DREADD-expressing control mice. ∗P < 0.05 between genotypes and within drug treatment (Bonferroni post-test). n = 11–14. Veh, vehicle; CNO, clozapine-N-oxide.